Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5081287
Max Phase: Preclinical
Molecular Formula: C40H72N12O9
Molecular Weight: 865.09
Molecule Type: Unknown
Associated Items:
ID: ALA5081287
Max Phase: Preclinical
Molecular Formula: C40H72N12O9
Molecular Weight: 865.09
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](C)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
Standard InChI: InChI=1S/C40H72N12O9/c1-22(2)20-28(34(55)46-25(6)33(54)48-27(39(60)61)13-9-17-45-40(43)44)49-35(56)30-14-11-19-52(30)38(59)29(21-23(3)4)50-36(57)31-15-10-18-51(31)37(58)26(12-7-8-16-41)47-32(53)24(5)42/h22-31H,7-21,41-42H2,1-6H3,(H,46,55)(H,47,53)(H,48,54)(H,49,56)(H,50,57)(H,60,61)(H4,43,44,45)/t24-,25+,26-,27-,28-,29-,30-,31-/m0/s1
Standard InChI Key: PJEWAUHKNFUYAI-TUSWLNAQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 865.09 | Molecular Weight (Monoisotopic): 864.5545 | AlogP: -1.67 | #Rotatable Bonds: 25 |
Polar Surface Area: 337.36 | Molecular Species: ZWITTERION | HBA: 11 | HBD: 11 |
#RO5 Violations: 3 | HBA (Lipinski): 21 | HBD (Lipinski): 14 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.94 | CX Basic pKa: 13.64 | CX LogP: -4.10 | CX LogD: -7.34 |
Aromatic Rings: 0 | Heavy Atoms: 61 | QED Weighted: 0.03 | Np Likeness Score: 0.04 |
1. Gorman DM, Li XX, Lee JD, Fung JN, Cui CS, Lee HS, Rolfe BE, Woodruff TM, Clark RJ.. (2021) Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity., 64 (22.0): [PMID:34762432] [10.1021/acs.jmedchem.1c01174] |
Source(1):